Study involving late-onset disease shows Evrysdi acts on certain mRNA molecules Written by Andrea Lobo | Oct. 21, 2026 Treating adults with late-onset spinal muscular atrophy (SMA) with Evrysdi (risdiplam) partially normalized changes in certain RNA molecules found in blood, a study found.
The main current treatment for giant cell arteritis includes the daily use of glucocorticoids, especially prednisone. Unfortunately, glucocorticoids can impact patients with serious side effects such as weight gain, diabetes, osteoporosis, high blood pressure, and infections. In addition to measuring…
ICMR funds a four-year study to uncover genetic and immunological links in multiplex autoimmune families, aiming to reveal disease mechanisms and therapy targets. Updated - October 29, 2026 08:27 pm IST The Indian Council of Medical Research has funded a four-year study to investigate…
RESEARCHERS have found that anti-CD20 treatment in multiple sclerosis (MS) has been associated with a higher risk of inflammatory bowel disease (IBD) than other modern disease-modifying therapy (DMT) options, according to a new Swedish population-based cohort study. Anti-CD20 biologics have…
A toxic union for neurons Given these results, the researchers designed an innovative strategy to trick the Poly-GR dipeptides and reduce their toxicity. They created a trap, a molecule that mimicked the specific rRNA sequence to which Poly-GR dipeptides bin…
Novartis has presented positive results from two phase 3 trials measuring its BTK inhibitor, remibrutinib, against teriflunomide for patients with relapsing multiple sclerosis (RMS). The trials showed that remibrutinib reduced relapse rates to approximately one every 13 years and enabled more than…
“It hurts really bad.” That’s a completely valid way to describe pain. But when you’re sitting in a doctor’s office trying to figure out why something hurts, your healthcare provider may need more details. Where is the pain? When did…
Uncover the latest and most impactful research in Gait Assessment and Intervention in Multiple Sclerosis. Explore pioneering discoveries, insightful ideas and new methods from leading researchers in the field. Thank you for visiting nature.com. You are using a browser…
Three Phase III studies have demonstrated the potential for fenebrutinib to address both relapsing and progressive disease, thereby bringing us closer to an oral treatment that could make a meaningful difference across the MS spectrum." The NDA for fenebrutinib is…
— Potential treatment for relapsing and progressive MS under FDA priority review The investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib may curb chronic active lesions in multiple sclerosis (MS), data from phase III trials suggested. Two MRI biomarkers in MS are…
Multiple sclerosis: treatments, the Epstein-Barr virus link, research and people living with MS.
An article joins this feed when it matches these terms. Each one is also a search of its own.